Abstract
Preliminary findings from the first clinical trials of cannabis in the UK have yielded some encouraging results of its use for the alleviation of pain. Data presented at the recent British Association for the Advancement of Sciences Annual Festival showed that the majority of the 23 patients studied so far experienced relief of pain associated with multiple sclerosis or other ailments. The improved effectiveness of cannabis in these studies compared with previous studies is attributed to the novel mode of delivery, a sublingual spray. The trials are now being expanded with plans to recruit up to 660 multiple sclerosis suffers for the three-year programme. DC
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
